

AMARIN CORP PLC\UK
Form 8-K
March 04, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 4, 2014

Amarin Corporation plc

(Exact name of registrant as specified in its charter)

England and Wales
(State or other jurisdiction

of incorporation)

0-21392
(Commission

File Number)

Not applicable
(I.R.S. Employer

Identification No.)

2 Pembroke House, Upper Pembroke Street 28-32,

Dublin 2, Ireland
(Address of principal executive offices)

Not applicable
(Zip Code)

Registrant's telephone number, including area code: +353 1 6699 020

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On March 4, 2014, Amarin Pharmaceuticals Ireland Limited, a wholly owned subsidiary of Amarin Corporation plc (Amarin), filed a complaint in the United States District Court for the District of Delaware against Omthera Pharmaceuticals, Inc., a Delaware corporation, and its parent company, AstraZeneca Pharmaceuticals LP. The suit seeks injunctive relief and monetary damages for infringement of Amarin's U.S. Patent No. 8,663,662 (the Patent), which was issued by the United States Patent and Trademark Office today. The complaint alleges infringement of the Patent arising from the expected launch of Epanova™ in the United States. The Patent covers methods of lowering triglycerides by administering a pharmaceutical composition that includes amounts of EPA as free acid, and no more than about 30% DHA. Amarin intends to pursue this litigation vigorously and aggressively protect its intellectual property rights.

Patent litigation is a time-consuming and costly process. There can be no guarantee that Amarin will be successful in enforcing the Patent or that the Patent will not be successfully challenged and invalidated. Even if Amarin is successful in enforcing the Patent, the process could take years to reach conclusion.

Forward-looking statements

This Current Report on Form 8-K contains forward-looking statements, including statements about Amarin's plan to pursue the litigation vigorously and aggressively protect its intellectual property rights, whether Amarin will be successful in enforcing the Patent, the patent litigation process generally and whether Amarin will obtain the remedies sought. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include the following: events that could interfere with the continued validity or enforceability of the Patent; Amarin's ability generally to successfully enforce patent claims against third parties; Amarin's decisions to devote sufficient resources to the above-described enforcement action; and uncertainties associated generally with litigation. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

* * *

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 4, 2014

Amarin Corporation plc

By: /s/ John Thero

John Thero

President and Chief Executive Officer